CN1118687A - synergistic norfloxacin drinking agent - Google Patents
synergistic norfloxacin drinking agent Download PDFInfo
- Publication number
- CN1118687A CN1118687A CN 95110255 CN95110255A CN1118687A CN 1118687 A CN1118687 A CN 1118687A CN 95110255 CN95110255 CN 95110255 CN 95110255 A CN95110255 A CN 95110255A CN 1118687 A CN1118687 A CN 1118687A
- Authority
- CN
- China
- Prior art keywords
- norfloxacin
- trimethoprim
- sodium chloride
- nicotinic acid
- mixing
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229960001180 norfloxacin Drugs 0.000 title claims abstract description 36
- OGJPXUAPXNRGGI-UHFFFAOYSA-N norfloxacin Chemical compound C1=C2N(CC)C=C(C(O)=O)C(=O)C2=CC(F)=C1N1CCNCC1 OGJPXUAPXNRGGI-UHFFFAOYSA-N 0.000 title claims abstract description 35
- 230000035622 drinking Effects 0.000 title claims abstract description 13
- 230000002195 synergetic effect Effects 0.000 title abstract 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 claims abstract description 42
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims abstract description 39
- 229960003512 nicotinic acid Drugs 0.000 claims abstract description 21
- 235000001968 nicotinic acid Nutrition 0.000 claims abstract description 21
- 239000011664 nicotinic acid Substances 0.000 claims abstract description 21
- 239000011780 sodium chloride Substances 0.000 claims abstract description 20
- IEDVJHCEMCRBQM-UHFFFAOYSA-N trimethoprim Chemical compound COC1=C(OC)C(OC)=CC(CC=2C(=NC(N)=NC=2)N)=C1 IEDVJHCEMCRBQM-UHFFFAOYSA-N 0.000 claims abstract description 20
- 229960001082 trimethoprim Drugs 0.000 claims abstract description 20
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims abstract description 19
- 239000008103 glucose Substances 0.000 claims abstract description 19
- 238000002156 mixing Methods 0.000 claims abstract description 15
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims abstract description 12
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 12
- 238000001035 drying Methods 0.000 claims abstract description 3
- 238000012856 packing Methods 0.000 claims description 10
- 239000000203 mixture Substances 0.000 claims description 9
- 239000000126 substance Substances 0.000 claims description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 7
- 229960001031 glucose Drugs 0.000 claims description 5
- -1 mixing Substances 0.000 claims description 5
- 238000012216 screening Methods 0.000 claims description 5
- 239000007864 aqueous solution Substances 0.000 claims description 4
- 238000005453 pelletization Methods 0.000 claims description 4
- 229910052731 fluorine Inorganic materials 0.000 claims description 3
- 239000011737 fluorine Substances 0.000 claims description 3
- 239000007921 spray Substances 0.000 claims description 3
- 229960002668 sodium chloride Drugs 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims 3
- YCKRFDGAMUMZLT-UHFFFAOYSA-N Fluorine atom Chemical compound [F] YCKRFDGAMUMZLT-UHFFFAOYSA-N 0.000 claims 2
- FGCSIJPPCNCQJB-FAOVPRGRSA-M sodium;(2r,3s,4r,5r)-2,3,4,5,6-pentahydroxyhexanal;chloride Chemical compound [Na+].[Cl-].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O FGCSIJPPCNCQJB-FAOVPRGRSA-M 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 6
- 241000894006 Bacteria Species 0.000 description 19
- 239000003814 drug Substances 0.000 description 12
- 239000007788 liquid Substances 0.000 description 11
- 241000287828 Gallus gallus Species 0.000 description 8
- 235000013330 chicken meat Nutrition 0.000 description 8
- 229940079593 drug Drugs 0.000 description 6
- 206010039438 Salmonella Infections Diseases 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 206010039447 salmonellosis Diseases 0.000 description 5
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 230000036285 pathological change Effects 0.000 description 4
- 231100000915 pathological change Toxicity 0.000 description 4
- 239000000273 veterinary drug Substances 0.000 description 4
- 230000001580 bacterial effect Effects 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 244000144977 poultry Species 0.000 description 3
- 235000013594 poultry meat Nutrition 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- 238000012795 verification Methods 0.000 description 3
- 206010012735 Diarrhoea Diseases 0.000 description 2
- 208000032843 Hemorrhage Diseases 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- 230000003115 biocidal effect Effects 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 239000003651 drinking water Substances 0.000 description 2
- 235000020188 drinking water Nutrition 0.000 description 2
- 230000000857 drug effect Effects 0.000 description 2
- 229960000304 folic acid Drugs 0.000 description 2
- 235000019152 folic acid Nutrition 0.000 description 2
- 239000011724 folic acid Substances 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 230000010534 mechanism of action Effects 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 210000002976 pectoralis muscle Anatomy 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- TZLPBVURAWCOKX-UHFFFAOYSA-N 2-benzyl-4-methoxypyrimidine Chemical compound COC1=CC=NC(CC=2C=CC=CC=2)=N1 TZLPBVURAWCOKX-UHFFFAOYSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 241000272525 Anas platyrhynchos Species 0.000 description 1
- 241000272814 Anser sp. Species 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 241000252983 Caecum Species 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 208000003322 Coinfection Diseases 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- 206010020565 Hyperaemia Diseases 0.000 description 1
- 206010033971 Paratyphoid fever Diseases 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 241000607142 Salmonella Species 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 210000003484 anatomy Anatomy 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 230000037358 bacterial metabolism Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 210000004534 cecum Anatomy 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229940060038 chlorine Drugs 0.000 description 1
- 210000001268 chyle Anatomy 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 230000000994 depressogenic effect Effects 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 238000009313 farming Methods 0.000 description 1
- 210000003746 feather Anatomy 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 230000002070 germicidal effect Effects 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 238000005286 illumination Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- QWLISCJHYITNQF-UHFFFAOYSA-N n-methoxy-1-phenylmethanamine Chemical compound CONCC1=CC=CC=C1 QWLISCJHYITNQF-UHFFFAOYSA-N 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 208000037921 secondary disease Diseases 0.000 description 1
- 208000013223 septicemia Diseases 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
Landscapes
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
A synergistic norfloxacin drinking agent is prepared from norfloxacin (4-6%), trimethoprim (0.5-0.5%) and nicotinic acid (2-3%) except glucose and sodium chloride through mixing, granulating and drying, and features high curative effect, and high curative effect.
Description
The invention belongs to the veterinary drug technical field, is a kind of synergy norfloxacin drinking agent.
At present, in the veterinary drug technical field, have only the folk prescription norfloxacin injection, norfloxacin drinking agent, norfloxacin compound injection antibiotic with it give mixture etc.Said medicine has certain germicidal efficacy.
The purpose of this invention is to provide a kind of good water solubility, be convenient to the fowl poultry and drink, curative effect is better than the synergy norfloxacin drinking agent of folk prescription norfloxacin drinking agent.
The object of the present invention is achieved like this: the present invention is made up of norfloxacin, trimethoprim, nicotinic acid, glucose and sodium chloride,
Norfloxacin 4%-6%
The close pyridine 0.5%-1.5% of methoxy benzyl ammonia
Nicotinic acid 2%-3%
Glucose 61.5%
The sodium chloride surplus
Above-mentioned composition can adopt three kinds of its preparation process
1, nicotinic acid is made aqueous solution, be sprayed onto in norfloxacin and the methoxy benzyl pyrimidine, mixed pelletization, oven dry, crushing screening adds glucose and sodium chloride, mixing, chemical examination packing.
2, the husky star of promise chlorine, trimethoprim and nicotinic acid three mix, water is sprayed onto on the mixture, mixing, granulate, dry, sieve all to pieces, add glucose, sodium chloride mixing again, the chemical examination packing.
3, norfloxacin, trimethoprim and nicotinic acid mixing add glucose, sodium chloride mixing, chemical examination, packing again.
Good water solubility of the present invention is convenient to the fowl poultry and is drunk, through clinical verification, and clinical verification P of the present invention＜0.01, curative effect is very remarkable.
Norfloxacin content of the present invention is identical with folk prescription norfloxacin drinking agent content, and trimethoprim is lower than 0.5% or be higher than at 1.5% o'clock, and drug effect strengthens not obvious; For making product have water solublity, it is an amount of that nicotinic acid is wanted, and its content is not less than 2%, is not higher than 3%.
The mechanism of action of norfloxacin is to suppress the DNA of bacteria gyrase, and blocking dna is synthetic, thereby produces the quick sterilization effect.
The mechanism of action of trimethoprim is to the dihydrofoilic acid in the bacterial metabolism process, reductase is inhibited, can block the metabolism of folic acid, the generation of bacterial nucleic acid is suppressed, with norfloxacin synergism is arranged, the two use in conjunction can make the synthetic and folic acid metabolism of the DNA of antibacterial be subjected to double blocking, and drug effect is strengthened.Nicotinic acid makes norfloxacin and trimethoprim have water solublity.Glucose and sodium chloride are the adjuvant filler, increase the flowability of medicine.The present invention is a broad spectrum antibiotic, G+ and G-pathogenic bacterium all there is killing action, can be used for treating diarrhoea such as Pullorum Disease, piglet, Hakuri, yellow scours, chicken, duck, goose, cattle, horse, sheep, septicemia, paratyphoid fever etc. are used when being particularly suitable for fowl poultry acute bacterial infectious disease or mixed infection.
Further specify technical characterictic of the present invention below in conjunction with embodiment.
Embodiment 1: get norfloxacin 5g
Trimethoprim 1g
Nicotinic acid 2.5g
Glucose 61.5g
Sodium chloride 30g
Nicotinic acid is made aqueous solution, and spray wine mixed pelletization, oven dry, is pulverized, is sieved in norfloxacin and trimethoprim, adds glucose and sodium chloride, mixing, chemical examination, packing again.
Embodiment 2: get norfloxacin 5g
Trimethoprim 1.5g
Nicotinic acid 2.5g
Glucose 61.5g
Sodium chloride 29.5g
Norfloxacin, trimethoprim and nicotinic acid three mix, and will be sprayed onto on the mixture, mixing, granulation, drying, crushing screening, add glucose, sodium chloride again, and mixing is chemically examined packing.
Embodiment 3: get norfloxacin 4g
Trimethoprim 0.5g
Nicotinic acid 2g
Glucose 61.5g
Sodium chloride 32g
Norfloxacin, trimethoprim and nicotinic acid three mix and add glucose again, and sodium chloride mixes chemical examination, packing.
Embodiment 4: get norfloxacin 6g
Trimethoprim 1.5g
Nicotinic acid 3g
Glucose 61.5g
Sodium chloride 28g
Nicotinic acid is made aqueous solution, spray wine in norfloxacin and trimethoprim, mixed pelletization, oven dry, crushing screening adds glucose again, sodium chloride mixing, chemical examination packing.
The present invention carries out the clinical verification therapeutic test to the chickling salmonellosis.Get medicine 50 gram/bags of the present invention, get control drug folk prescription norfloxacin drinking agent, produce 50 gram/bags by Shandong veterinary drug subsidiary factory.Get standard lyophilization Pullorum Disease salmonella strain (S.Pullovum) bacterium G9-13, provide by China Veterinary Drugs Supervisory Inst..Getting standard Pullorum antigen and immune serum goes out the Harbin veterinary institute and provides.
Supply liquid preparation of examination bacterium and bacterium liquid to contain bacterium and count algoscopy, the lyophilizing bacterial strain is incubated at broth medium, put 37 ℃ of incubators and increase bacterium cultivation 24 hours, after smear for microscopic examination and affirmation have this bacterium breeding of growth type; It is inoculated in the plain agar slant medium, puts 37 ℃ and cultivated 18 hours, wash bacterium colony with sterile saline and make bacterium liquid (hereinafter to be referred as bacterium liquid), calculating bacterial concentration by plate surface count plate method is 3.4 hundred million jin/ml.
Laboratory animal is through the non-immune 6 age in days Bai Nike chickens of the no salmonellosis of quarantine, and body weight 50～60 restrains/only, provided by Shenyang City's herding institute.
Experiment provides no medicine mixed feed with feedstuff by Liaoning Province's great achievement farming and animal husbandry company limited, feeds after the assay was approved through feedstuff monitoring station, Liaoning Province, and day feed three times is freely drunk water.
Experiment condition, 18～32 ℃ of room temperatures, relative humidity 60～70% illumination manual adjustment.
Experimental technique: get 120 of experimental chickens, be divided into four groups at random.
The A group: artificial challenge's trial drug treatment group bacterium liquid adds medicine of the present invention.
The B group: the similar medication therapy groups bacterium of artificial challenge liquid adds the folk prescription norfloxacin.
C group: not medication of artificial challenge group, bacterium liquid.
More than three groups be the equal conditions drylot feeding.
A, B, C adopt the chest muscle injecting method to carry out Pullorum Disease salmonellosis artificial challenge for three groups simultaneously.Every chicken injection bacterium liquid 0.5ml (bacteria containing amount is 1.7 hundred million).
The artificial challenge is after 24 hours for A, B group, medication according to dosage respectively, twice of every day.
48～72 little phase secondary diseases behind A, B, three groups of artificial challenges of C, spirit is depressed, the wing that hangs down, dysnystaxis, just from green feces, nephrodinic ambient contamination, feather is fluffy and disorderly, the Pullorum Disease classical symptom occurs.A, B are organized continuous use five days, continue after the drug withdrawal to observe seven days, A organizes dead 2, B organizes dead 4, C organizes dead 21, after 13 days dead chicken and survival chicken are dissected one by one, observed the pathological change of its intestinal, kidney, liver and lung, indicate with "-" "+" " ++ " " +++" respectively according in various degree pathological changes.
Experimental result shows that the present invention is sick to the typical case of gram bacillus, and the Pullorum Disease salmonellosis has the obvious treatment effect, observe from pathological anatomy, the pathological change of C group is generally serious, and liver is hemorrhage, the white condition of illness that the needle point size occurs, hyperemia, the down visible white downright bad shape of lung serous coat, the dirty petechial hemorrhage of stomach, enteral is seen and is watered red chyle shape thing, caecum is seen the ulcer shape, and rectum sees that the cyan loose stool stops up intestinal, and two groups of only indivedual chickens of A, B have pathological changes.
The present invention and prior art are to exquisite white scour of chicken salmonellosis of treatment people result of the test comparison sheet.(seeing Table 1) table 1
| Component | The chickling number of elements | Chest muscle injection volume (ml) | Injected material | The medicine name | Liquor strength (%) | Administering mode | Observe natural law | Dead number of elements | Mortality rate (% | The survival number of elements | Survival rate % | ???X 2 |
| ?A | ?30 | ????0.5 | Bacterium liquid | Medicine of the present invention | ?0.2 | Drinking-water | ??15 | ???2 | ???7 | ??28 | ??93 | ?P＜0.01 |
| ?B | ?30 | ????0.5 | Bacterium liquid | The husky amount of folk prescription promise fluorine | ?0.2 | Drinking-water | ??15 | ???5 | ??17 | ??25 | ??83 | ?P＜0.05 |
| ?C | ?30 | ????0.5 | Bacterium liquid | Not administration | ??15 | ??17 | ??57 | ??13 | ??43 |
Claims (4)
1, a kind of synergy norfloxacin drinking agent, it is by norfloxacin, and trimethoprim, nicotinic acid, glucose and sodium chloride are formed, and it is characterized in that:
Norfloxacin 4%～6%
Trimethoprim 0.5%～1.5%
Nicotinic acid 2%～3%
Glucose 61.5%
The sodium chloride surplus
2, the manufacturing process of the husky amount of a kind of potentiation promise fluorine drinking agent is characterized in that, nicotinic acid is made aqueous solution, and spray wine is in norfloxacin and trimethoprim, and mixed pelletization, oven dry, crushing screening add glucose and sodium chloride, mixing, chemical examination packing.
3, a kind of manufacturing process of synergy norfloxacin drinking agent is characterized in that, norfloxacin, trimethoprim and nicotinic acid three mix, and water is sprayed onto on the mixture, and mixing is granulated, drying, and crushing screening adds glucose again, sodium chloride mixing, chemical examination packing.
4, the manufacturing process of the husky amount of a kind of potentiation promise fluorine drinking agent is characterized in that norfloxacin, trimethoprim and nicotinic acid mixing add glucose sodium chloride, mixing, chemical examination, packing again.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 95110255 CN1118687A (en) | 1995-05-24 | 1995-05-24 | synergistic norfloxacin drinking agent |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 95110255 CN1118687A (en) | 1995-05-24 | 1995-05-24 | synergistic norfloxacin drinking agent |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN1118687A true CN1118687A (en) | 1996-03-20 |
Family
ID=5077657
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 95110255 Pending CN1118687A (en) | 1995-05-24 | 1995-05-24 | synergistic norfloxacin drinking agent |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1118687A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104666401A (en) * | 2015-03-17 | 2015-06-03 | 成都乾坤动物药业有限公司 | Veterinary Chinese and western medicinal compound orally-disintegrating micropowder tablet and preparation method thereof |
-
1995
- 1995-05-24 CN CN 95110255 patent/CN1118687A/en active Pending
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104666401A (en) * | 2015-03-17 | 2015-06-03 | 成都乾坤动物药业有限公司 | Veterinary Chinese and western medicinal compound orally-disintegrating micropowder tablet and preparation method thereof |
| CN104666401B (en) * | 2015-03-17 | 2019-03-05 | 成都乾坤动物药业股份有限公司 | A kind of Chinese and Western medicine compound mouth for animals collapses micropowder tablet and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Taoka et al. | Use of live and dead probiotic cells in tilapia Oreochromis niloticus | |
| Touraki et al. | Evaluation of the probiotics Bacillus subtilis and Lactobacillus plantarum bioencapsulated in Artemia nauplii against vibriosis in European sea bass larvae (Dicentrarchus labrax, L.) | |
| CN102697784B (en) | Enrofloxacin injection for livestock and preparation method thereof | |
| CN1907358A (en) | Pharmaceutical composition for preventing and treating avian coccidiosis and its preparing method | |
| CN114736875B (en) | Riemerella anatipestifer phage, phage composition and application thereof | |
| CN103989725A (en) | Acalypha australis L. and amikacin containing compound medicine for livestock and poultry | |
| CN1837348A (en) | Culture solution and preservation solution for coccidian oocyst | |
| CN103989726A (en) | Acalypha australis L. and fosfomycin containing compound medicine for livestock and poultry | |
| CN1632105A (en) | Bacillus subtilis preparation | |
| CN111821322A (en) | Poultry micro-ecological oral preparation capable of replacing antibiotics and application thereof | |
| CN106620668A (en) | Compound tilmicosin solid dispersing agent and preparation method thereof | |
| EP1894995B1 (en) | Irilis biopreparation based on bacillus-strain bacteria, bacillus subtilis and bacillus licheniformis contained therein | |
| CN1118687A (en) | synergistic norfloxacin drinking agent | |
| CN108815151A (en) | Purposes of the lauroyl arginine ethyl ester as feed addictive | |
| CN104337847A (en) | Compound medicine containing bracken and fosfomycin for livestock | |
| Chadfield et al. | Evaluation of treatment and prophylaxis with nitrofurans and comparison with alternative antimicrobial agents in experimental Salmonella enterica serovar enteritidis infection in chicks | |
| CN111991384A (en) | Protocatechuic acid and application of compound protocatechuic acid thereof in improving performance of livestock and poultry | |
| Wilson et al. | Evaluation of two aryl‐fluoroquinolones against bacterial pathogens of channel catfish | |
| CN102764252A (en) | Application of valnemulin hydrochloride | |
| CN101829129A (en) | Veterinary compound gentamycin sulfate injection and preparation method thereof | |
| CN1299684C (en) | Aquatic animal antibacterial agent and preparation method thereof | |
| CN102908610B (en) | Propolis combination used for livestock and preparation method of same | |
| CN102462686A (en) | Pharmaceutical composition used for preventing and treating colibacillosis in livestock and poultry | |
| CN104435995B (en) | Purposes of the tsaoko in preparing treatment and/or preventing the herbal medicine of colibacillosis | |
| CN102058815B (en) | Application of Chinese cardamon oil to preparing medicament for treating bacterial infectious diseases |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C06 | Publication | ||
| PB01 | Publication | ||
| C01 | Deemed withdrawal of patent application (patent law 1993) | ||
| WD01 | Invention patent application deemed withdrawn after publication |